Home Blog Page 2
On Friday afternoon, CASI Pharma CEO He Wei-Wu filed a Form 4 disclosing the purchase of nearly $7.9M of CASI stock. The insider bought the shares in a public offering of 20M CASI shares at $1.90. President Larry Zhang also bought 20,153 shares in the secondary offering, his first as a CASI insider. Rockville,...
The Securities and Exchange Commission has proposed significantly raising the size threshold of funds required to file quarterly 13F disclosures. The SEC 13F rule change would end quarterly portfolio filings for nearly 90% of current filers. The proposal would raise the AUM threshold that investment managers must meet every quarter from $100 million...
Two Bed Bath & Beyond insiders bought shares as the slumping retailer published an investor update describing improving June sales trends. After announcing dismal Q1 Covid-19-impacted earnings on July 8, Bed Bath & Beyond (BBBY) management received lots of questions from investors. So on Tuesday, the company released a list of "Frequently Asked Questions." In the Q&A,...
The ten most underrated hedge funds are not famous. But the managers running these funds have consistently generated exceptional returns despite (or maybe because) they fly under the radar. The stock picks of the managers on this list have handily outperformed most of the "wizards of finance" Wall Street gushes over. Investors seeking...
Below is a list of the top ten most overrated hedge fund managers. Many of these guys (they're all men) have become celebrities, idolized by investors, just like movie stars or great athletes are in mainstream American society. And most of them made their billions -- and forged their reputations -- years ago. Recent performance doesn't rise...
On June 17, EcoR1 Capital filed a 13G on Xencor Inc. (XNCR), disclosing the purchase of over 2M shares. EcoR1 now owns 8% of Xencor. The purchase makes XNCR the #1 position in EcoR1's $957M 13F portfolio. Xencor is a clinical-stage biopharmaceutical company developing therapies for the treatment of cancer and autoimmune diseases....
For Akre Capital Management Founder Charles Akre, investment success is all about the power of compounding. As Akre puts it, "Many people think of us as a 'value investor' and others ask whether we are a value or a growth investor. We’ve started to say, we’re neither, we are a compounding investor." Whatever you call it, Akre's...
Mauricio Leyva, appointed in March to the newly-created role of President, International and Business Development at Keurig Dr. Pepper (KDP) made a big buy of KDP on Monday. In a Form 4 filed yesterday, Leyva disclosed the purchase of 123,400 KDP at $28.47. The $3.58M buy was the Keurig Dr Pepper insider Leyva's first since joining...
At the Sohn San Francisco Investment Conference last year, Gil Simon of SoMa Equity Partners presented his best idea: SailPoint Technologies (SAIL). The Sohn conference is renowned as an annual event where hedge fund managers make market-moving presentations. Indeed, after Simon -- a rising star in the hedge fund world -- made his pitch, SAIL stock went...
The S&P 500 traded above its 200 day moving average last week for the first time since March 5. Back on March 23, at the bottom of the crash, the index was 28% below its 200 Day MA. The market has seen an amazing "bounce" since then. But many stocks -- mainly those hurt most by the...